宫内抗癫痫药物暴露的神经认知结局:澳大利亚队列研究
这项半前瞻性队列研究纳入110名3-18岁儿童,评估宫内暴露于卡马西平、拉莫三嗪、左乙拉西坦、丙戊酸或托吡酯单药治疗与未暴露儿童的神经认知结局。结果显示托吡酯和左乙拉西坦暴露与最大的全面智商差异相关,拉莫三嗪暴露儿童表现与未暴露者相当。研究提供II级证据表明除拉莫三嗪外,其他四种药物暴露与更差的神经认知结局相关。
要点
- 托吡酯和左乙拉西坦暴露与最大的全面智商差异相关
- 拉莫三嗪暴露儿童认知表现与未暴露同龄人相当
- 丙戊酸、左乙拉西坦、托吡酯和卡马西平暴露与多个认知域较低得分相关
核心结论
- 宫内暴露于托吡酯、左乙拉西坦、丙戊酸和卡马西平与领域特异性认知脆弱性相关,尤其影响智商、处理速度和学业功能。
- 托吡酯和左乙拉西坦暴露与未暴露儿童相比智商差异最大。
- 拉莫三嗪暴露儿童的认知表现与未暴露同龄人相当,提示其在认知结局方面可能相对更安全。
研究设计与样本
- 半前瞻性队列研究,纳入110名3-18岁儿童,来自Raoul Wallenberg澳大利亚抗癫痫药物妊娠登记。
- 暴露组包括卡马西平(n=20)、拉莫三嗪(n=23)、左乙拉西坦(n=20)、丙戊酸(n=19)或托吡酯(n=11)单药治疗,未暴露组n=19。
- 由对产前抗癫痫药物暴露状态不知情的神经心理学家进行标准化神经心理评估,使用广义线性混合效应模型调整母亲智商、癫痫特征和相关围产期因素。
主要发现
- 110名儿童平均年龄9.6岁,51%为女性;91名暴露于抗癫痫药物单药治疗,19名未暴露。
- 丙戊酸、左乙拉西坦、托吡酯或卡马西平暴露儿童在多个认知域得分较低,包括处理速度、言语理解、视空间推理和学业技能(Cohen d范围=-0.8至-1.0)。
- 全面智商差异最大的是托吡酯(b=-17.4,95%CI -30.6至-6.1)和左乙拉西坦(b=-13.9,95%CI -24.5至-3.8)。
- 拉莫三嗪暴露儿童表现与未暴露同龄人相当。
- 认知结局未随抗癫痫药物剂量变化,可能因样本量较小。
关键数值与推荐
- 主要结局包括韦氏智力量表的全面智商(FSIQ)和指数得分;次要结局评估学业技能、记忆、语言和执行功能。
- 研究提供II级证据表明宫内暴露于丙戊酸、左乙拉西坦、托吡酯和卡马西平(而非拉莫三嗪)与儿童更差的神经认知结局相关。
临床怎么用
- 对于癫痫女性妊娠期用药,拉莫三嗪暴露与未暴露儿童认知表现相当,可作为认知结局方面相对更安全的选择。
- 托吡酯和左乙拉西坦暴露与最大的智商差异相关,临床决策时需权衡胎儿神经认知风险。
- 丙戊酸暴露在本队列中影响似乎减弱,但仍与多个认知域较低得分相关,应谨慎使用。
局限性
- 认知结局未随抗癫痫药物剂量变化,可能因样本量较小。
- 各组样本量较小(如托吡酯n=11),可能影响统计效能和剂量-效应分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Continuation of antiseizure medication (ASM) during pregnancy is essential for seizure control in most women with epilepsy, yet few studies have characterized the neurocognitive phenotypes associated with prenatal ASM exposure, with limited data on newer agents. The aim of this study was to determine whether in utero exposure to specific types of ASM monotherapies is associated with poorer neurocognitive outcomes compared with ASM-unexposed children. METHODS: This semiprospective cohort study included children aged 3-18 years born to women enrolled in the Raoul Wallenberg Australian Pregnancy Register of Antiepileptic Drugs. Children without major congenital anomalies who were exposed prenatally to carbamazepine (n = 20), lamotrigine (n = 23), levetiracetam (n = 20), valproate (n = 19), or topiramate (n = 11) monotherapy, or who were unexposed to ASMs (n = 19), were followed from birth and underwent standardized neuropsychological assessment by a neuropsychologist blinded to prenatal ASM exposure status. Primary outcomes included Full-Scale IQ (FSIQ) and index scores from the Wechsler Intelligence Scales; secondary outcomes assessed academic skills, memory, language, and executive functions. Generalized linear mixed-effects models were used to estimate associations between prenatal ASM exposure and cognitive outcomes, adjusting for maternal IQ, epilepsy characteristics, and relevant perinatal factors. RESULTS: Of 110 children assessed (mean age 9.6 years; 51% female), 91 were exposed to ASM monotherapy in utero and 19 were unexposed. Children exposed to valproate, levetiracetam, topiramate, or carbamazepine scored lower across multiple cognitive domains, including processing speed, verbal comprehension, visuospatial reasoning, and academic skills (Cohen d range = -0.8 to -1.0). The largest FSIQ differences were observed for topiramate (b = -17.4, 95% CI -30.6 to -6.1) and levetiracetam (b = -13.9, 95% CI -24.5 to -3.8). Lamotrigine-exposed children showed performance comparable to unexposed peers. Cognitive outcomes did not vary by ASM dose, likely because of smaller sample sizes. DISCUSSION: Prenatal exposure to topiramate, levetiracetam, valproate, and carbamazepine was associated with domain-specific cognitive vulnerabilities, particularly in IQ, processing speed, and academic functioning. Topiramate and levetiracetam exposure were linked to the largest IQ differences compared with unexposed children. While valproate is typically associated with the greatest risk, its impact seemed attenuated in this cohort. By contrast, cognitive performance in lamotrigine-exposed children was comparable to unexposed peers, suggesting that it may be comparatively safer with respect to cognitive outcomes. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in utero exposure to valproate, levetiracetam, topiramate, and carbamazepine, but not to lamotrigine, is associated with worse neurocognitive outcomes in children compared with unexposed children.
引用
- Honybun E, Malpas CB, Graham JE, et al. Neurocognitive Outcomes of In Utero Exposure to Antiseizure Medication: An Australian Cohort Study. Neurology. 2026. PMID: 42247656. doi:10.1212/WNL.0000000000218122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。